INNV Innovus Pharmaceuticals, Inc.

Website: http://www.innovuspharma.com

Share Statistics
Avg Vol (3 month)3: 485,965
Avg Vol (10 day)3: 1,392,510
Shares Outstanding5: 67.55M
Float: 38.25M


Business Summary
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company’s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

http://www.innovuspharma.com/


Innovus Pharma CEO Provides Shareholder Update and Conference Call
http://finance.yahoo.com/news/innovus-pharma-ceo-provides-shareholder-101000536.html

 

I took .26 during armature hour. I never will learn, so impatient. It pulled back nicely and almost filled the gap. Nice volume and not a bad close at all. Thinking more of the lines of 6 months for up listing if they can get the revs going and FDA approval for FlutiCare. Talked to them for a bit today and they pointed out from today's PR... With potential approval the product is anticipated to be commercially available during early 2017. Also talked about their convertibles, they didn't seem concerned as some have already been cleared and there shouldn't be a problem clearing the rest. Talked about them doing a RS to expedite uplisting as well, they do not like that idea (thankfully) and that the revs should boost the pps to be able to take advantage of the lower tier NYSE ($2).
See how it goes. I've seen this company mentioned in the past but never really did any dd till today. I have another OTC (OBMP) that is also well under the radar, small bites once in a while when I can. Worth the DD. Some of these stay hidden for some reason and then bang! No reason to dive in without doing your research though.

Cheers Gil!!

 

I'm in already, but will also be chasing lol. Measure your risk of course but will also be looking more into 2017. An intent to up list legitimately without a reverse split is not an overnight feat. They need to hold the $2 for at least 30 days or longer.

 

Thanks Russ!

 

INNV had a bit of a shake to test support, not surprising really. Getting some nice attention helps clear the convertibles imo. Conference call Wednesday is sparking some FDA rumors. It's possible I guess. See what happens!

 

Sideways due to some conversions that took this down. Looking like they're about done but this has melted away a lot of the enthusiasm. Looking for some anticipation to start back up soon.

 

Nice:
Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra® in Lebanon


Innovus Eligible to Receive up to $2.25 Million in Sales Milestone Payments Plus Transfer Pricing


November 08, 2016 06:00 AM Eastern Standard Time


SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV) announced today it has entered into its second exclusive license and distribution agreement with Elis Pharmaceuticals, Ltd. (“Elis Pharma”). Under the agreement Innovus Pharma granted to Elis an exclusive license to market and sell Zestra® for female arousal and desire in Lebanon. Innovus Pharma is eligible to receive up to $2.25 million in sales milestone payments plus an agreed-upon transfer price.


“This second partnership highlights our excitement about Innovus Pharma’s unique and innovative products”
Tweet this
Bassam Damaj, President and Chief Executive Officer of Innovus Pharma, commented, “We are very excited about this second commercial partnership collaboration with Elis. Zestra® was commercialized in Lebanon by Semprae Labs prior to being acquired by Innovus Pharma. We look forward to working with Elis Pharma to re-establish market presence of Zestra® in Lebanon. We continue to be focused on executing on our goals of making our products commercially available in markets outside of the United States and achieving our goal of profitability in 2017.”

“This second partnership highlights our excitement about Innovus Pharma’s unique and innovative products,” said Mr. Rashed Assouma, CEO of Elis Pharmaceuticals. “In this region Elis Pharma has over 1,000 products, including the exclusive license to Vitaros® for erectile dysfunction licensed from Apricus Biosciences, and we have a dedicated sales force targeting urologists and gynecologists in Lebanon. Zestra® is a well-respected and known brand in Lebanon by gynecologists and consumers, and we look forward to getting the required government approval to re-launch Zestra® in the near future.”

Zestra® is currently commercialized in the U.S. by Innovus Pharma, in Canada by Orimed Pharma, in Africa by Sothema Labs, in Hong Kong by PT Laras Bumi Resources, and in select European countries by Danalife.

Zestra® has also received approval in India and the United Arab Emirates.

About Zestra® and FSI/AD

Zestra® is a patented blend of natural oils clinically proven in double-blind, placebo-controlled clinical trials in 276 women to increase in a statistically significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada. To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity, causing personal distress. Published papers on the FSI/AD market size estimate it to be equal to or larger than the market for erectile dysfunction in males, and possibly larger.

About Elis Pharmaceuticals, Ltd.

Elis Pharmaceuticals markets and distributes over 1,000 branded and generic pharmaceuticals and under-licensed products. Established in the United Arab Emirates, Elis Pharmaceuticals’ fast growth has allowed it to become a global company, with a strong focus on the Middle East and North Africa and Turkey. Elis Pharmaceuticals serves over 40 markets and has strengthened its presence by collaborating with multinational companies.

For more information, visit Elis Pharmaceuticals’ website at www.elispharmaceuticals.com.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men's and women's health and respiratory diseases. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation, and has an additional five marketed products in this space, including (e) Sensum+® to help with reduced penile sensitivity, (f) Zestra Glide®, (g) Vesele® for promoting sexual health, (h) RecalMax™ for promoting brain and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others, and eventually FlutiCare™ OTC for allergic rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com, www.ejectdelay.com, www.myvesele.com, www.sensumplus.com, www.myandroferti.com, www.beyondhumantestosterone.com, www.getbeyondhuman.com, www.trybeyondhuman.com, www.recalmax.com, www.urivarx.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, results from the above pre-clinical and clinical trial, projected revenues, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.


Contacts

Chesapeake Group
Kevin Holmes, 410-825-3930
[email protected]


http://www.businesswire.com/news/ho...igns-Exclusive-License-Distribution-Agreement

http://www.google.ca/finance?q=OTCMKTS:INNV&ei=Rt8hWIKsG4iwmAGG5rrwCA